BRPI0717282A2 - Novos antígenos e anticorpos associados ao adenocarcinoma ductal pancreático - Google Patents

Novos antígenos e anticorpos associados ao adenocarcinoma ductal pancreático Download PDF

Info

Publication number
BRPI0717282A2
BRPI0717282A2 BRPI0717282-6A BRPI0717282A BRPI0717282A2 BR PI0717282 A2 BRPI0717282 A2 BR PI0717282A2 BR PI0717282 A BRPI0717282 A BR PI0717282A BR PI0717282 A2 BRPI0717282 A2 BR PI0717282A2
Authority
BR
Brazil
Prior art keywords
pda
enolase
alpha
antibodies
enoa
Prior art date
Application number
BRPI0717282-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Novelli Francesco
Tomaino Barbara
Cappello Paola
Original Assignee
Ribovax Biotechnologies Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribovax Biotechnologies Sa filed Critical Ribovax Biotechnologies Sa
Publication of BRPI0717282A2 publication Critical patent/BRPI0717282A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01011—Phosphopyruvate hydratase (4.2.1.11), i.e. enolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI0717282-6A 2006-09-29 2007-09-28 Novos antígenos e anticorpos associados ao adenocarcinoma ductal pancreático BRPI0717282A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06121552.1 2006-09-29
EP06121552 2006-09-29
EP06126726.6 2006-12-20
EP06126726 2006-12-20
PCT/EP2007/060305 WO2008037792A1 (en) 2006-09-29 2007-09-28 Novel antigens and antibodies associated to pancreatic ductal adenocarcinoma

Publications (1)

Publication Number Publication Date
BRPI0717282A2 true BRPI0717282A2 (pt) 2013-10-15

Family

ID=38895810

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717282-6A BRPI0717282A2 (pt) 2006-09-29 2007-09-28 Novos antígenos e anticorpos associados ao adenocarcinoma ductal pancreático

Country Status (18)

Country Link
US (1) US8071721B2 (https=)
EP (1) EP2069395B1 (https=)
JP (1) JP2010505104A (https=)
KR (1) KR20090094227A (https=)
CN (1) CN101578295B (https=)
AT (1) ATE542831T1 (https=)
AU (1) AU2007301966B2 (https=)
BR (1) BRPI0717282A2 (https=)
CA (1) CA2664841A1 (https=)
DK (1) DK2069395T3 (https=)
EA (1) EA016731B1 (https=)
ES (1) ES2381304T3 (https=)
IL (2) IL197868A (https=)
NO (1) NO20091662L (https=)
NZ (1) NZ576409A (https=)
PL (1) PL2069395T3 (https=)
PT (1) PT2069395E (https=)
WO (1) WO2008037792A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120003225A1 (en) * 2008-05-09 2012-01-05 Duke University Autoantibodies in the detection and treatment of cancer
IT1398782B1 (it) * 2009-09-11 2013-03-18 Novelli Peptide monofosforilato isolato derivato dall'alfa-enolasi umana utile per la diagnosi e il trattamento dell'adenocarcinoma pancreatico, anticorpi diretti contro il suddetto peptide monofosforilato e loro usi.
ITTO20120523A1 (it) * 2012-06-15 2013-12-16 Natimab Therapeutics S R L Procedimento e kit per la diagnosi in vitro dell'adenocarcinoma duttale pancreatico o per determinare la predisposizione all'adenocarcinoma duttale pancreatico
ES2729797T3 (es) * 2013-12-20 2019-11-06 Dev Ct Biotechnology Anticuerpos específicos de la alfa-enolasa y métodos de uso en terapias contra el cáncer
US10188708B2 (en) 2014-01-13 2019-01-29 Berg Llc Enolase 1 (Eno1) compositions and uses thereof
CN115786317B (zh) * 2022-12-12 2026-03-20 江苏三联生物工程股份有限公司 重组神经元特异性烯醇化酶及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753446A (en) * 1993-04-15 1998-05-19 National Jewish Center For Immunology & Respiratory Medicine Mitogen ERK kinase kinase (MEKK) assay

Also Published As

Publication number Publication date
US20100028907A1 (en) 2010-02-04
WO2008037792A1 (en) 2008-04-03
PL2069395T3 (pl) 2012-06-29
CA2664841A1 (en) 2008-04-03
EA200970332A1 (ru) 2009-10-30
ATE542831T1 (de) 2012-02-15
EA016731B1 (ru) 2012-07-30
NZ576409A (en) 2012-02-24
IL197868A0 (en) 2011-08-01
IL218442A0 (en) 2012-04-30
NO20091662L (no) 2009-06-29
KR20090094227A (ko) 2009-09-04
EP2069395B1 (en) 2012-01-25
CN101578295A (zh) 2009-11-11
DK2069395T3 (da) 2012-05-14
PT2069395E (pt) 2012-04-27
AU2007301966B2 (en) 2013-02-21
AU2007301966A1 (en) 2008-04-03
ES2381304T3 (es) 2012-05-25
US8071721B2 (en) 2011-12-06
CN101578295B (zh) 2013-02-27
EP2069395A1 (en) 2009-06-17
IL197868A (en) 2013-03-24
JP2010505104A (ja) 2010-02-18

Similar Documents

Publication Publication Date Title
Wang et al. CPT 1A‐mediated succinylation of S100A10 increases human gastric cancer invasion
Gomes et al. Glycoproteomic analysis of serum from patients with gastric precancerous lesions
BRPI0717282A2 (pt) Novos antígenos e anticorpos associados ao adenocarcinoma ductal pancreático
Wang et al. Diagnostic and prognostic value of protein post-translational modifications in hepatocellular carcinoma
US20130287801A1 (en) Biomarkers, uses of biomarkers and a method of identifying biomarkers
Caballero et al. Chicken GRIFIN: a homodimeric member of the galectin network with canonical properties and a unique expression profile
Martucciello et al. Anti-type 2 transglutaminase antibodies as modulators of type 2 transglutaminase functions: a possible pathological role in celiac disease
Sheng et al. SENP1-mediated deSUMOylation of YBX1 promotes colorectal cancer development through the SENP1-YBX1-AKT signaling axis
Lu et al. Benchmark of site-and structure-specific quantitative tissue N-glycoproteomics for discovery of potential N-glycoprotein markers: a case study of pancreatic cancer
Afshari et al. Glycoproteoforms of osteoarthritis-associated lubricin in plasma and synovial fluid
EP3042203B1 (en) Biomarkers for cholangiocellular carcinoma (ccc)
Arielly et al. Quantitative analysis of caveolin-rich lipid raft proteins from primary and metastatic colorectal cancer clones
ES2625259T3 (es) Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón
Thakar et al. SUMOylation of the hepatoma‐derived growth factor negatively influences its binding to chromatin
JP2015042641A (ja) 壊死マーカー及びその用途
Zurawel et al. Proteomic profiling of the mesenteric lymph after hemorrhagic shock: differential gel electrophoresis and mass spectrometry analysis
Dziadosz-Brzezińska et al. Considerations for antibody-based detection of NRF2 in human cells
Kobayashi et al. Acquisition of useful sero-diagnostic autoantibodies using the same patients’ sera and tumor tissues
BRPI0611703A2 (pt) modificações da isoforma do cspcna e seus usos
Postic et al. Over‐expression of Dyrk1A affects bleeding by modulating plasma fibronectin and fibrinogen level in mice
Hintze et al. The ligand preference of LRP1 is regulated by O-glycans
Chalova et al. Inhibitory Effect of Human Anti‐CA I Autoantibodies and Development of Monoclonal Antibody mAb 2B8 Targeting Carbonic Anhydrase I
Tian et al. USP13 Regulates the Breast Tumor Proliferation and Migration through the Stabilization of PDCD4 Protein
Mu et al. Screening of multiple myeloma by polyclonal rabbit anti-human plasmacytoma cell immunoglobulin
Autoantigen DEK in the Synovium of Patients With Juvenile Idiopathic Arthritis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2277 DE 26/08/2014.